Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
Joint Authors
Adejumo, Adeyinka Charles
Adegbala, Oluwole Muyiwa
Adejumo, Kelechi Lauretta
Bukong, Terence Ndonyi
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-23
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background and Aim.
The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial.
Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals.
Methods.
We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis.
We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS).
We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.).
Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm.
We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4].
Results.
Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs).
However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]).
Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]).
Conclusions.
Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients.
These novel observations warrant further molecular mechanistic studies.
American Psychological Association (APA)
Adejumo, Adeyinka Charles& Adegbala, Oluwole Muyiwa& Adejumo, Kelechi Lauretta& Bukong, Terence Ndonyi. 2018. Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1131076
Modern Language Association (MLA)
Adejumo, Adeyinka Charles…[et al.]. Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1131076
American Medical Association (AMA)
Adejumo, Adeyinka Charles& Adegbala, Oluwole Muyiwa& Adejumo, Kelechi Lauretta& Bukong, Terence Ndonyi. Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1131076
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1131076